PI
Specialization
cardio-kidney-metabolic (CKM) disease, peritoneal dialysis, hemodialysis, sodium-glucose co-transporter 2 inhibition (SGLT2i), cardiovascular risk management in CKD and kidney failure
Focus of research
With my research I aim to improve understanding, prevention and treatment of the high cardiovascular disease (CVD) burden in patients with severe chronic kidney disease (CKD) and those treated with dialysis. In particular, my former and current translational projects focus on the immunometabolic risk factors and mechanisms underlying heart failure in patients with severe CKD and how these can be targeted by novel cardio-kidney-metabolic (CKM) therapies such as sodium-glucose co-transporter 2 inhibitors (SGLT2i).